Pain is a medical condition that interferes with normal human life and work and reduces human well-being worldwide. Human voltage-gated sodium channel NaV1.7 (hNaV1.7) is a compelling target that plays a key role in human pain signaling. The 33-residue peptide µ-TRTX-Hhn2b (HNTX-I), a member of NaV-targeting spider toxin (NaSpTx) family 1, has shown negligible activity on mammalian voltage-gated sodium channels (VGSCs), including the hNaV1.7 channel. We engineered analogues of HNTX-I based on sequence conservation in NaSpTx family 1. Substitution of Asn for Ser at position 23 or Asp for His at position 26 conferred potent activity against hNaV1.7. Moreover, multiple site mutations combined together afforded improvements in potency. Ultimately, we generated an analogue E1G–N23S–D26H–L32W with >300-fold improved potency compared with wild-type HNTX-I on hNaV1.7 (IC50 0.036 ± 0.007 µM). Structural simulation suggested that the charged surface and the hydrophobic surface of the modified peptide are responsible for binding affinity to the hNaV1.7 channel, while variable residues may determine pharmacological specificity. Therefore, this study provides a profile for drug design targeting the hNaV1.7 channel.
28 August 2023 in International Journal of Biological Macromolecules
Sodium channels play a critical role in the generation and propagation of action potentials in excitable tissues, such as nerves, cardiac muscle, and skeletal muscle, and are the primary targets of toxins found in animal venoms. Here, two novel peptide toxins (Cl6a and Cl6b) were isolated from the venom of the spider Cyriopagopus longipes and characterized. Cl6a and Cl6b were shown to be inhibitors of tetrodotoxin-sensitive (TTX-S), but not TTX-resistant, sodium channels. Among the TTX-S channels investigated, Cl6a and Cl6b showed the highest degree of inhibition against NaV1.7 (half-maximal inhibitory concentration (IC50) of 11.0 ± 2.5 nM and 18.8 ± 2.4 nM, respectively) in an irreversible manner that does not alter channel activation, inactivation, or repriming kinetics. Moreover, analysis of NaV1.7/NaV1.8 chimeric channels revealed that Cl6b is a site 4 neurotoxin. Site-directed mutagenesis analysis indicated that D816, V817, and E818 observably affected the efficacy of the Cl6b-NaV1.7 interaction, suggesting that these residues might directly affect the interaction of NaV1.7 with Cl6b. Taken together, these two novel peptide toxins act as potent and sustained NaV1.7 blockers and may have potential in the pharmacological study of sodium channels.
The voltage-gated sodium channel NaV1.7 is a pivotal therapeutic target for the developing novel, potent, and specific analgesics. HWTX-I, a peptide isolated from the venom of the tarantula Ornithoctonus huwena, is known to inhibit N-type calcium channels and has also been demonstrated to block tetrodotoxin-sensitive (TTX-S) NaV channels in dorsal root ganglion (DRG) neurons. In this study, we show that HWTX-I potently inhibits NaV1.7 currents with an IC50 value of 40.6 ± 16.1 nM, but it does not significantly affect the voltage dependence of NaV1.7 steady-state activation and inactivation. Alanine-scanning mutagenesis revealed that residues K3, V5, F6, P11, N14, E15, W28, and K30 are critical for HWTX-I's inhibitory activity against NaV1.7. Furthermore, site-directed mutagenesis analysis demonstrated that HWTX-I binds to the S3-S4 linker in domain II (DII) of NaV1.7, and the D816K mutation in NaV1.7 significantly abrogates the efficacy of the HWTX-I-NaV1.7 interaction. Molecular dynamics (MD) simulations combined with free energy decomposition analysis identified NaV1.7-D816 and HWTX-I-K3 as dominant energetic contributors to binding, consistent with a role for long-range electrostatic steering rather than a persistent short-range salt bridge. Collectively, these findings elucidate the structural basis of HWTX-I-NaV1.7 binding, identify the pharmacophore of the toxin, and provide valuable insights into the interactions between peptide toxins and NaV1.7. Therefore, this research may guide the future development of specific, safe, and efficacious NaV1.7 inhibitors for pain relief.